American Century Companies’s Vaxcyte PCVX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$45.5M Buy
782,184
+426,330
+120% +$23.2M 0.02% 897
2026
Q1
$20.7M Sell
355,854
-1,446
-0.4% -$78.5K 0.01% 1171
2025
Q4
$16.5M Buy
357,300
+13,273
+4% +$594K 0.01% 1248
2025
Q3
$12.4M Sell
344,027
-7,025
-2% -$233K 0.01% 1347
2025
Q2
$11.4M Sell
351,052
-236,002
-40% -$7.74M 0.01% 1320
2025
Q1
$22.2M Sell
587,054
-18,213
-3% -$1.46M 0.01% 995
2024
Q4
$49.5M Buy
605,267
+76,262
+14% +$7.57M 0.03% 628
2024
Q3
$60.4M Buy
529,005
+1,411
+0.3% +$127K 0.04% 527
2024
Q2
$39.8M Buy
527,594
+65,870
+14% +$4.48M 0.02% 660
2024
Q1
$31.5M Buy
461,724
+54,495
+13% +$3.77M 0.02% 740
2023
Q4
$25.6M Buy
407,229
+35,487
+10% +$1.84M 0.02% 777
2023
Q3
$19M Buy
371,742
+9,099
+3% +$449K 0.01% 823
2023
Q2
$18.1M Buy
+362,643
New +$17.2M 0.01% 818
2023
Q1
– Sell
-8,062
Closed -$387K – 2686
2022
Q4
$387K Buy
+8,062
New +$316K ﹤0.01% 2136

Other funds holding PCVX

American Century Companies's PCVX Position: Q2 2026 in Review

American Century Companies increased its Vaxcyte (PCVX) stake by 120% in Q2 2026, buying an estimated $23.2M and bringing the position to 782,184 shares worth $45.5M. The position accounts for 0.02% of the portfolio, ranked #897.

American Century Companies first reported a position in PCVX in Q4 2022 and has held it in 14 quarters since. The position peaked at $60.4M in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • American Century Companies held 782,184 shares of Vaxcyte worth $45.5M as of Q2 2026.
  • American Century Companies bought 426,330 Vaxcyte shares in Q2 2026, an estimated $23.2M.
  • Vaxcyte made up 0.02% of American Century Companies's portfolio in Q2 2026, its #897 holding.
  • American Century Companies first reported a position in Vaxcyte in Q4 2022 and has held it in 14 quarters since.
  • American Century Companies's Vaxcyte position peaked at $60.4M in Q3 2024.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.